10-K: THC Therapeutics Inc. Reports Annual Results, Focuses on dHydronator Development

THC Therapeutics, Inc. reported its annual results, highlighting a focus on the development of its dHydronator herb dryer and ongoing financial challenges.

Summary

• THC Therapeutics, Inc. is a development-stage company focused on the wellness industry, specifically the development of the dHydronator, a sanitizing herb dryer.
• The dHydronator is designed to dry and sanitize cannabis and other herbs, reducing drying time to 10-14 hours compared to traditional methods that can take up to two weeks.
• The company has a functioning prototype of the dHydronator and plans to source parts for serial manufacturing once sufficient funds are available.
• For the fiscal year ended July 31, 2023, the company reported an operating loss of $493,912 and a net loss of $387,036.
• The company has an accumulated deficit of approximately $38.4 million as of July 31, 2023.
• The company did not generate any revenue during the fiscal years ending July 31, 2023 and 2022.
• The company's cash balance was $10 as of July 31, 2023, and it has a working capital deficit of $3,221,843.
• The company anticipates needing approximately $3,810,000 over the next 12 months to implement its plan of operations.
• The company is subject to the SEC's penny stock rules, which may make it difficult for broker-dealers to complete customer transactions.
• The company has outstanding preferred stock with special rights that could limit its ability to undertake corporate transactions.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a lack of revenue, substantial losses, and a going concern warning, which results in a negative sentiment.

Positives

• The company has a patented product, the dHydronator, with proven laboratory results.
• The dHydronator has the potential to significantly reduce drying time for cannabis and other herbs.
• The company has a functioning prototype of the dHydronator.
• The company has reduced its operating loss by $1,252,116 compared to the previous fiscal year.

Negatives

• The company has not generated any revenue during the fiscal years ending July 31, 2023 and 2022.
• The company has a significant accumulated deficit of approximately $38.4 million.
• The company has a very low cash balance of $10 as of July 31, 2023.
• The company has a working capital deficit of $3,221,843.
• The company is subject to the SEC's penny stock rules, which may make it difficult for broker-dealers to complete customer transactions.
• The company has outstanding preferred stock with special rights that could limit its ability to undertake corporate transactions.
• The company's internal controls over financial reporting were deemed ineffective.

Risks

• There is substantial doubt about the company's ability to continue as a going concern.
• The company may not be able to raise the necessary capital to continue operations.
• The company has a history of losses and may incur future losses.
• Federal drug regulation and enforcement may adversely impact the company's operations.
• The company's products may become subject to regulation by the FDA, which would increase costs.
• The company may not be able to achieve its strategic initiatives and grow its business as anticipated.
• The company has a history of changing and discontinuing operations.
• The company may be deemed an investment company under the Investment Company Act.
• The company may fail to protect its intellectual property.
• The company's products may be subject to recalls.
• The company's future success depends on its ability to retain its chief executive officer and other key executives.
• The company's common stock is subject to the SEC's penny stock rules.
• The market price of the company's common stock may be volatile.
• The company has never paid and does not intend to pay cash dividends.
• The company's executive officer and director have the ability to control all matters submitted to stockholders for approval.
• The company will incur increased costs as a result of operating as a public reporting company.
• The company may issue instruments which are convertible into shares of common stock, which will result in additional dilution.

Future Outlook

The company intends to engage in further development efforts for the dHydronator, including finalizing case design, manufacturing pre-production units, hiring subject-matter experts, and engaging in market research, once it has at least $2,000,000 in available cash flow or funds from other operations and if it receives the patent.

Management Comments

• The following discussion and analysis should be read in conjunction with our consolidated financial statements for THC Therapeutics, Inc. Such discussion represents only the best present assessment from our Management.
• Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the consolidated financial statements are issued and determined that substantial doubt exists about the Company's ability to continue as a going concern.

Industry Context

The company operates in the wellness industry, specifically targeting the cannabis and home herb and garden product markets with its dHydronator herb dryer. The company faces competition from other commercial herb dryer manufacturers.

Comparison to Industry Standards

• The document mentions Yofumo Technologies as a competitor with significant market share in commercial herb dryers.
• The dHydronator aims to reduce drying time to 10-14 hours, compared to traditional methods that can take up to two weeks, which is a significant improvement.
• The company's proprietary sanitizing technology reduced the total aerobic count (TAC) from over 300,000 CFU/g to 78,000 CFU/g in testing, which is below the passing threshold of 100,000 CFU/g.
• The company's test results indicate that the dHydronator can reduce moisture content to 10-15%, which is within the optimal range of 8-12% for cannabis.

Management Changes

Legal Proceedings

• The company was involved in a lawsuit with Iliad Research and Trading, L.P., which was settled on January 31, 2024.
• The company was previously involved in lawsuits with Power Up Lending Group, Ltd., and its former CEO, Parker Mitchell, which have been settled.

Related Party Transactions

• The company has received advances from its CEO, Brandon Romanek, and his father, Harvey Romanek.
• The company has a convertible promissory note with Harvey Romanek.
• The company has an employment agreement with its CEO, Brandon Romanek.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial challenges.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers are not yet impacted as the company does not have any customers yet.

Next Steps

• The company plans to source parts for serial manufacturing of the dHydronator.
• The company plans to hire sales and marketing staff.
• The company plans to engage in further detailed laboratory testing of the dHydronator.
• The company plans to establish a relationship with a market research and/or marketing company.
• The company intends to hire subject matter expert consultants or employees in the legal cannabis and home herb marketplace.

Key Dates

Keywords

dHydronator, herb dryer, cannabis, sanitizing, wellness, patent, financial results, operating loss, net loss, penny stock, intellectual property, capital raise